Basis for Immunotherapy for Treatment of Sporadic Vestibular Schwannoma
Journal of Neurological Surgery Part B: Skull Base · 13.05.2026
DOI: 10.1055/a-2868-0897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 13.05.2026. Verfasst von Shivani Chowdhary und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Vestibular schwannoma (VS) is managed with observation, surgery, or radiation, but treatment-refractory cases pose significant clinical challenges. With recurrence rates of 30.7% after subtotal resection and 5 to 15% radiation failure rates, salvage therapies carry substantial morbidity, including facial nerve injury (30–50%) and cerebrospinal fluid leak (15–20%), highlighting the urgent need for novel therapeutic approaches.
Design
Narrative review of current literature.
Setting
Literature review of published clinical reports, early-phase trials, and translational research studies in VS.
Participants
Patients with VS and experimental tumor models. Main Outcome Measures Tumor growth control, recurrence rates, characterization of the VS tumor microenvironment, and evaluation of immunotherapeutic strategies.
Results
The VS tumor microenvironment provides a compelling rationale for immunotherapy, with tumor-associated macrophages comprising up to one-third of tumor mass in aggressive cases. Merlin-deficient tumor cells upregulate PD-L1 and secrete cytokines (M-CSF, TNF-α, IL1β, IL-6) that create a paradoxically inflammatory yet immunosuppressive microenvironment through T-cell anergy and sustained PD1/PD-L1 engagement. Although clinical evidence remains limited, consisting of isolated case reports and a single small uncontrolled pilot trial in NF2-associated disease, preliminary results provide hypothesis-generating data. Theoretical and preclinical strategies under early investigation include CAR-T cell therapy, combination checkpoint blockade with anti-angiogenics, and novel delivery platforms for enhanced skull base access. Biomarker development remains critical for patient selection, with candidates including PD-L1 expression, tumor-infiltrating lymphocyte profiles, and dynamic markers like treatment-induced regulatory T cell depletion.
Conclusion
Success requires multi-institutional collaboration, adaptive trial designs, and rational combination strategies addressing the complex immunosuppressive mechanisms within VS. While the biological rationale is compelling, the field remains in an exploratory phase with no firm therapeutic conclusions possible at this stage. Rigorous prospective investigation is needed before immunotherapy can be considered a viable treatment strategy for sporadic VS.
Zitieren
APA
Chowdhary, S., Walton, C. M., Bell, M., Miller, A., Dixon, P., & Strickland, B. A. (2026). Basis for Immunotherapy for Treatment of Sporadic Vestibular Schwannoma. Journal of Neurological Surgery Part B: Skull Base. https://doi.org/10.1055/a-2868-0897
Vancouver
Chowdhary S, Walton CM, Bell M, Miller A, Dixon P, Strickland BA. Basis for Immunotherapy for Treatment of Sporadic Vestibular Schwannoma. Journal of Neurological Surgery Part B: Skull Base. 2026. doi:10.1055/a-2868-0897
BibTeX
@article{Chowdhary2026,
author = {Chowdhary, Shivani and Walton, Chase M. and Bell, Marcus and Miller, Aaron and Dixon, Peter and Strickland, Ben A.},
title = {Basis for Immunotherapy for Treatment of Sporadic Vestibular Schwannoma},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2026},
doi = {10.1055/a-2868-0897}
}
EUVIMED